New drug shows promise against multiple sclerosis

Ocrelizumab is a humanized anti-CD20 monoclonal antibody, targeting mature B lymphocytes. It reduced the formation of brain lesions, and the number of new multiple sclerosis attacks over 24 weeks.A simular strategy using a related drug, Rituximab was also recently shown to be  effective in chronic fatigue syndrome. Both drugs attack autoimmunity.

Multiple sclerosis